2023
164-LB: Durable Improvement in HbA1c in Youth-Onset T2D—A Post Hoc Analysis of the DINAMO Trial of Empagliflozin and Linagliptin vs. Placebo
LAFFEL L, DANNE T, TAMBORLANE W, KLINGENSMITH G, NEUBACHER D, TARTAKOVSKY I, MARQUARD J, ZEITLER P, WILLI S. 164-LB: Durable Improvement in HbA1c in Youth-Onset T2D—A Post Hoc Analysis of the DINAMO Trial of Empagliflozin and Linagliptin vs. Placebo. Diabetes 2023, 72 DOI: 10.2337/db23-164-lb.Peer-Reviewed Original ResearchHbA1c <Increasing prevalence of childhood overweightGlycemic controlPrevalence of childhood overweightSafety of empagliflozinLinagliptin 5 mgClinically meaningful responseYouth-onset T2DOnset of complicationsBeta-cell functionPost hoc analysisEmpagliflozin groupClinical courseFPG levelsChildhood overweightSGLT2 inhibitorsEmpagliflozinYouth-onsetPlaceboHbA1c changeMeaningful responseHbA1cHigher HbA1cHoc analysisIncreased prevalence
2018
Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry
Tamborlane WV, Chang P, Kollman C, Klingensmith GJ, Ruedy K, Gal RL, Van Name M, Bacha F, Willi S, Beck RW, Consortium F. Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry. Pediatric Diabetes 2018, 19: 1379-1384. PMID: 30175440, DOI: 10.1111/pedi.12763.Peer-Reviewed Original ResearchConceptsType 2 diabetesT2D durationT2D patientsClinical trialsEligibility criteriaPlacebo-assigned subjectsPercentage of patientsCurrent clinical trialsRestrictive eligibility criteriaBaseline HbA1cHbA1c levelsClinical characteristicsClinic registryRegistry enrollmentInvestigational treatmentPatientsCurrent trialTrialsNew drugsMonthsHbA1cRatio of femaleDiabetesRegistryEnrollment
2017
Initial Presentation of Type 2 Diabetes in Adolescents Predicts Durability of Successful Treatment with Metformin Monotherapy: Insights from the Pediatric Diabetes Consortium T2D Registry
Bacha F, Cheng P, Gal RL, Kollman C, Tamborlane WV, Klingensmith GJ, Manseau K, Wood J, Beck RW. Initial Presentation of Type 2 Diabetes in Adolescents Predicts Durability of Successful Treatment with Metformin Monotherapy: Insights from the Pediatric Diabetes Consortium T2D Registry. Hormone Research In Paediatrics 2017, 89: 47-55. PMID: 29131017, DOI: 10.1159/000481687.Peer-Reviewed Original ResearchConceptsMetformin monotherapyType 2 diabetesLower HbA1cGroup 2Shorter diabetes durationYear of diagnosisAdequate controlDiabetes durationT2D durationGlycemic controlInitial presentationMultivariable analysisBMI percentileSuccessful treatmentBACKGROUND/Early diagnosisMonotherapyTherapy highlightGroup 1HbA1cMetabolic controlMetforminDiagnosisGreater likelihoodRapid deterioration
2015
Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry
Miller KM, Foster NC, Beck RW, Bergenstal RM, DuBose SN, DiMeglio LA, Maahs DM, Tamborlane WV. Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry. Diabetes Care 2015, 38: 971-978. PMID: 25998289, DOI: 10.2337/dc15-0078.Peer-Reviewed Original ResearchConceptsYears of ageType 1 diabetesT1D Exchange Clinic RegistryContinuous glucose monitoringDiabetic ketoacidosisSevere hypoglycemiaClinic registryMetabolic controlOutcome of treatmentOptimal metabolic controlRegistry findingsAdvanced diabetes technologiesAverage HbA1cMean hemoglobinYounger patientsCommon complicationCurrent treatmentNew therapiesAge 30HbA1cType 1DiabetesGlucose monitoringDiabetes technologyAgeGlycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison
McKnight JA, Wild SH, Lamb MJ, Cooper MN, Jones TW, Davis EA, Hofer S, Fritsch M, Schober E, Svensson J, Almdal T, Young R, Warner JT, Delemer B, Souchon PF, Holl RW, Karges W, Kieninger DM, Tigas S, Bargiota A, Sampanis C, Cherubini V, Gesuita R, Strele I, Pildava S, Coppell KJ, Magee G, Cooper JG, Dinneen SF, Eeg-Olofsson K, Svensson AM, Gudbjornsdottir S, Veeze H, Aanstoot HJ, Khalangot M, Tamborlane WV, Miller KM. Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabetic Medicine 2015, 32: 1036-1050. PMID: 25510978, DOI: 10.1111/dme.12676.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAustriaDenmarkDiabetes Mellitus, Type 1EnglandFemaleFranceGermanyGlycated HemoglobinGreeceGuideline AdherenceHumansHypoglycemic AgentsInsulinInsulin Infusion SystemsIrelandItalyLatviaMaleNetherlandsNew ZealandNorthern IrelandNorwayPractice Guidelines as TopicRegistriesScotlandSwedenUkraineUnited StatesWalesWestern AustraliaYoung Adult
2013
Pediatric diabetes consortium T1D New Onset (NeOn) study: clinical outcomes during the first year following diagnosis
Cengiz E, Connor CG, Ruedy KJ, Beck RW, Kollman C, Klingensmith GJ, Tamborlane WV, Lee JM, Haller MJ, Consortium F. Pediatric diabetes consortium T1D New Onset (NeOn) study: clinical outcomes during the first year following diagnosis. Pediatric Diabetes 2013, 15: 287-293. PMID: 23944865, PMCID: PMC3844085, DOI: 10.1111/pedi.12068.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildChild, PreschoolCohort StudiesDiabetes Mellitus, Type 1Diabetic KetoacidosisDrug MonitoringFemaleFollow-Up StudiesGlycated HemoglobinHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsIncidenceInfantInsulinKaplan-Meier EstimateMaleProportional Hazards ModelsProspective StudiesUnited StatesConceptsPediatric Diabetes ConsortiumDiabetic ketoacidosisClinical outcomesNatural historyFirst yearCourse of T1DDiagnosis of T1D.Onset of T1DTime of diagnosisSevere hypoglycemic eventsType 1 diabetesMean HbA1cMulticenter studyHypoglycemic eventsClinical measuresLarge cohortIntervention studiesDiagnosisFuture interventionsMonthsOnset StudyHbA1cT1D.T1DOutcomes